T1	CHEM 21 28	TYSABRI
#1	AnnotatorNotes T1	C1529600
T2	CHEM 47 54	Tysabri
#2	AnnotatorNotes T2	C1529600
T3	CHEM 59 66	Tysabri
#3	AnnotatorNotes T3	C1529600
T4	OBJC 75 83	solution
#4	AnnotatorNotes T4	C0037633
T5	PROC 98 107	perfusion
#5	AnnotatorNotes T5	C0031001
T6	PROC 110 140	goutte-à-goutte dans une veine
#6	AnnotatorNotes T6	C0021440
T7	ANAT 135 140	veine
#7	AnnotatorNotes T7	C0042449
T8	CHEM 162 176	principe actif
#8	AnnotatorNotes T8	C1372955
T9	CHEM 177 188	natalizumab
#9	AnnotatorNotes T9	C1172734
T10	CHEM 207 214	Tysabri
#10	AnnotatorNotes T10	C1529600
T11	CHEM 234 241	Tysabri
#11	AnnotatorNotes T11	C1529600
T12	PROC 262 272	traitement
#12	AnnotatorNotes T12	C0087111
T13	LIVB 277 284	adultes
#13	AnnotatorNotes T13	C0001675
T14	DISO 297 316	sclérose en plaques
#14	AnnotatorNotes T14	C0026769
T15	DISO 319 322	SEP
#15	AnnotatorNotes T15	C0026769
T16	CHEM 336 343	Tysabri
#16	AnnotatorNotes T16	C1529600
T17	PROC 366 376	traitement
#17	AnnotatorNotes T17	C0087111
T18	CHEM 381 388	Tysabri
#18	AnnotatorNotes T18	C1529600
T19	LIVB 432 439	médecin
#19	AnnotatorNotes T19	C0031831
T20	PROC 460 470	traitement
#20	AnnotatorNotes T20	C0087111
T21	DISO 475 502	maladies du système nerveux
#21	AnnotatorNotes T21	C0027765
T22	DISO 475 483	maladies
#22	AnnotatorNotes T22	C0012634
T23	ANAT 487 502	système nerveux
#23	AnnotatorNotes T23	C0027763
T24	OBJC 541 548	scanner
#24	AnnotatorNotes T24	C0029140
T25	PROC 571 604	imagerie par résonance magnétique
#25	AnnotatorNotes T25	C0024485
T26	PROC 607 610	IRM
#26	AnnotatorNotes T26	C0024485
T27	LIVB 643 650	médecin
#27	AnnotatorNotes T27	C0031831
T28	ANAT 689 696	cerveau
#28	AnnotatorNotes T28	C0006104
T29	DISO 706 709	SEP
#29	AnnotatorNotes T29	C0026769
T30	DISO 719 728	infection
#30	AnnotatorNotes T30	C0021311
T31	ANAT 737 744	cerveau
#31	AnnotatorNotes T31	C0006104
T32	DISO 755 795	leucoencéphalite multifocale progressive
#32	AnnotatorNotes T32	C0023524
T33	DISO 798 802	LEMP
#33	AnnotatorNotes T33	C0023524
T34	CHEM 808 815	Tysabri
#34	AnnotatorNotes T34	C1529600
T35	PROC 834 843	perfusion
#35	AnnotatorNotes T35	C0031001
T36	PROC 906 915	perfusion
#36	AnnotatorNotes T36	C0031001
T37	DISO 951 970	réaction allergique
#37	AnnotatorNotes T37	C1527304
T38	LIVB 976 983	patient
#38	AnnotatorNotes T38	C0030705
T39	PROC 1033 1042	perfusion
#39	AnnotatorNotes T39	C0031001
T40	LIVB 1083 1090	patient
#40	AnnotatorNotes T40	C0030705
T41	DISO 1109 1114	signe
#41	AnnotatorNotes T41	C0037088
T42	LIVB 1155 1162	médecin
#42	AnnotatorNotes T42	C0031831
T43	PROC 1182 1192	traitement
#43	AnnotatorNotes T43	C0087111
T44	LIVB 1201 1209	patients
#44	AnnotatorNotes T44	C0030705
T45	PROC 1210 1217	traités
#45	AnnotatorNotes T45	C0087111
T46	CHEM 1222 1229	Tysabri
#46	AnnotatorNotes T46	C1529600
T47	CHEM 1336 1346	médicament
#47	AnnotatorNotes T47	C0013227
T48	LIVB 1354 1361	patient
#48	AnnotatorNotes T48	C0030705
T49	LIVB 1413 1426	aide-soignant
#49	AnnotatorNotes T49	C0028663
T50	LIVB 1446 1461	autres médecins
#50	AnnotatorNotes T50	C0334909
T51	DISO 1511 1528	symptômes de LEMP
#51	AnnotatorNotes T51	C0023524
T52	DISO 1511 1520	symptômes
#52	AnnotatorNotes T52	C1457887
T53	LIVB 1537 1544	patient
#53	AnnotatorNotes T53	C0030705
T54	DISO 1582 1603	variations d ’ humeur
#54	AnnotatorNotes T54	C0525045
T55	DISO 1609 1621	comportement
#55	AnnotatorNotes T55	C0004930
T56	DISO 1628 1635	langage
#56	AnnotatorNotes T56	C0023015
T57	CHEM 1654 1661	Tysabri
#57	AnnotatorNotes T57	C1529600
T58	LIVB 1749 1754	homme
#58	AnnotatorNotes T58	C0086418
T59	PROC 1764 1770	études
#59	AnnotatorNotes T59	C2603343
T60	CHEM 1836 1843	Tysabri
#60	AnnotatorNotes T60	C1529600
T61	DISO 1852 1855	SEP
#61	AnnotatorNotes T61	C0026769
T62	PROC 1875 1881	études
#62	AnnotatorNotes T62	C2603343
T63	CHEM 1892 1899	Tysabri
#63	AnnotatorNotes T63	C1529600
T64	CHEM 1938 1945	placebo
#64	AnnotatorNotes T64	C1696465
T65	PROC 1951 1968	traitement fictif
#65	AnnotatorNotes T65	C0032042
T66	PROC 1951 1961	traitement
#66	AnnotatorNotes T66	C0087111
T67	LIVB 1980 1988	patients
#67	AnnotatorNotes T67	C0030705
T68	PHEN 2071 2079	rechutes
#68	AnnotatorNotes T68	C0035020
T69	LIVB 2123 2131	patients
#69	AnnotatorNotes T69	C0030705
T70	DISO 2185 2193	handicap
#70	AnnotatorNotes T70	C0231172
T71	CHEM 2268 2275	Tysabri
#71	AnnotatorNotes T71	C1529600
T72	PROC 2289 2295	études
#72	AnnotatorNotes T72	C2603343
T73	CHEM 2300 2307	Tysabri
#73	AnnotatorNotes T73	C1529600
T74	CHEM 2355 2362	placebo
#74	AnnotatorNotes T74	C1696465
T75	DISO 2397 2400	SEP
#75	AnnotatorNotes T75	C0026769
T76	DISO 2446 2454	handicap
#76	AnnotatorNotes T76	C0231172
T77	CHEM 2493 2500	placebo
#77	AnnotatorNotes T77	C1696465
T78	LIVB 2509 2517	patients
#78	AnnotatorNotes T78	C0030705
T79	LIVB 2526 2541	aides-soignants
#79	AnnotatorNotes T79	C0028663
T80	LIVB 2549 2557	médecins
#80	AnnotatorNotes T80	C0031831
T81	CHEM 2586 2593	Tysabri
#81	AnnotatorNotes T81	C1529600
T82	DISO 2614 2624	infections
#82	AnnotatorNotes T82	C0021311
T83	DISO 2641 2645	LEMP
#83	AnnotatorNotes T83	C0023524
T84	DISO 2653 2657	LEMP
#84	AnnotatorNotes T84	C0023524
T85	DISO 2671 2680	symptômes
#85	AnnotatorNotes T85	C1457887
T86	DISO 2733 2736	SEP
#86	AnnotatorNotes T86	C0026769
T87	DISO 2765 2773	handicap
#87	AnnotatorNotes T87	C0231172
T88	PHYS 2786 2791	décès
#88	AnnotatorNotes T88	C0011065
T89	DISO 2819 2823	LEMP
#89	AnnotatorNotes T89	C0023524
T90	LIVB 2829 2836	médecin
#90	AnnotatorNotes T90	C0031831
T91	PROC 2853 2863	traitement
#91	AnnotatorNotes T91	C0087111
T92	LIVB 2919 2926	patient
#92	AnnotatorNotes T92	C0030705
T93	DISO 2951 2960	infection
#93	AnnotatorNotes T93	C0021311
T94	PROC 2978 2984	études
#94	AnnotatorNotes T94	C0010955
T95	DISO 2991 3010	effets indésirables
#95	AnnotatorNotes T95	C0559546
T96	CHEM 3045 3052	Tysabri
#96	AnnotatorNotes T96	C1529600
T97	LIVB 3069 3077	patients
#97	AnnotatorNotes T97	C0030705
T98	DISO 3111 3141	infections des voies urinaires
#98	AnnotatorNotes T98	C0042029
T99	DISO 3111 3121	infections
#99	AnnotatorNotes T99	C0021311
T100	ANAT 3126 3141	voies urinaires
#100	AnnotatorNotes T100	C0042027
T101	DISO 3144 3189	infection des structures véhiculant l ’ urine
#101	AnnotatorNotes T101	C0042029
T102	DISO 3144 3153	infection
#102	AnnotatorNotes T102	C0021311
T103	ANAT 3158 3189	structures véhiculant l ’ urine
#103	AnnotatorNotes T103	C0042027
T104	ANAT 3184 3189	urine
#104	AnnotatorNotes T104	C0042036
T105	DISO 3193 3208	rhinopharyngite
#105	AnnotatorNotes T105	C0027441
T106	ANAT 3227 3230	nez
#106	AnnotatorNotes T106	C0028429
T107	ANAT 3240 3245	gorge
#107	AnnotatorNotes T107	C0031354
T108	DISO 3249 3258	urticaire
#108	AnnotatorNotes T108	C0042109
T109	DISO 3261 3277	éruption cutanée
#109	AnnotatorNotes T109	C0042109
T110	DISO 3261 3269	éruption
#110	AnnotatorNotes T110	C0015230
T111	ANAT 3270 3277	cutanée
#111	AnnotatorNotes T111	C1123023
T112	DISO 3281 3293	maux de tête
#112	AnnotatorNotes T112	C0018681
T113	DISO 3296 3304	vertiges
#113	AnnotatorNotes T113	C0042571
T114	DISO 3307 3319	vomissements
#114	AnnotatorNotes T114	C0042963
T115	DISO 3322 3328	nausée
#115	AnnotatorNotes T115	C0027497
T116	DISO 3331 3341	arthralgie
#116	AnnotatorNotes T116	C0003862
T117	DISO 3344 3352	douleurs
#117	AnnotatorNotes T117	C0030193
T118	ANAT 3353 3365	articulaires
#118	AnnotatorNotes T118	C0022417
T119	DISO 3369 3377	frissons
#119	AnnotatorNotes T119	C0036973
T120	DISO 3380 3387	pyrexie
#120	AnnotatorNotes T120	C0015967
T121	DISO 3390 3396	fièvre
#121	AnnotatorNotes T121	C0015967
T122	DISO 3402 3409	fatigue
#122	AnnotatorNotes T122	C0015672
T123	DISO 3448 3467	effets indésirables
#123	AnnotatorNotes T123	C0559546
T124	CHEM 3482 3489	Tysabri
#124	AnnotatorNotes T124	C1529600
T125	PROC 3500 3506	notice
#125	AnnotatorNotes T125	C0013191
T126	CHEM 3511 3518	Tysabri
#126	AnnotatorNotes T126	C1529600
T127	LIVB 3553 3562	personnes
#127	AnnotatorNotes T127	C0027361
T128	DISO 3585 3601	hypersensibilité
#128	AnnotatorNotes T128	C0020517
T129	DISO 3604 3612	allergie
#129	AnnotatorNotes T129	C0020517
T130	CHEM 3618 3629	natalizumab
#130	AnnotatorNotes T130	C1172734
T131	LIVB 3705 3713	patients
#131	AnnotatorNotes T131	C0030705
T132	DISO 3727 3731	LEMP
#132	AnnotatorNotes T132	C0023524
T133	LIVB 3741 3749	patients
#133	AnnotatorNotes T133	C0030705
T134	DISO 3775 3784	infection
#134	AnnotatorNotes T134	C0021311
T135	LIVB 3801 3809	patients
#135	AnnotatorNotes T135	C0030705
T136	DISO 3834 3841	maladie
#136	AnnotatorNotes T136	C0012634
T137	PROC 3854 3864	traitement
#137	AnnotatorNotes T137	C0087111
T138	CHEM 3889 3896	Tysabri
#138	AnnotatorNotes T138	C1529600
T139	CHEM 3928 3943	interféron bêta
#139	AnnotatorNotes T139	C0015980
T140	CHEM 3953 3975	acétate de glatiramère
#140	AnnotatorNotes T140	C0289884
T141	CHEM 3953 3960	acétate
#141	AnnotatorNotes T141	C0000975
T142	CHEM 3989 4000	médicaments
#142	AnnotatorNotes T142	C0013227
T143	PROC 4018 4028	traitement
#143	AnnotatorNotes T143	C0087111
T144	DISO 4051 4054	SEP
#144	AnnotatorNotes T144	C0026769
T145	LIVB 4104 4112	patients
#145	AnnotatorNotes T145	C0030705
T146	DISO 4125 4131	cancer
#146	AnnotatorNotes T146	C0027651
T147	DISO 4166 4183	cancer de la peau
#147	AnnotatorNotes T147	C0007114
T148	ANAT 4179 4183	peau
#148	AnnotatorNotes T148	C1123023
T149	DISO 4191 4216	carcinome baso-cellulaire
#149	AnnotatorNotes T149	C0007117
T150	LIVB 4229 4235	sujets
#150	AnnotatorNotes T150	C0027361
T151	CHEM 4274 4281	Tysabri
#151	AnnotatorNotes T151	C1529600
T152	CHEM 4388 4395	Tysabri
#152	AnnotatorNotes T152	C1529600
T153	CHEM 4460 4467	Tysabri
#153	AnnotatorNotes T153	C1529600
T154	CHEM 4493 4500	Tysabri
#154	AnnotatorNotes T154	C1529600
T155	LIVB 4527 4535	médecins
#155	AnnotatorNotes T155	C0031831
T156	CHEM 4548 4555	Tysabri
#156	AnnotatorNotes T156	C1529600
T157	CHEM 4661 4671	médicament
#157	AnnotatorNotes T157	C0013227
T158	LIVB 4708 4716	patients
#158	AnnotatorNotes T158	C0030705
T159	CHEM 4781 4788	Tysabri
#159	AnnotatorNotes T159	C1529600
T160	GEOG 4807 4817	européenne
#160	AnnotatorNotes T160	C0015176
T161	GEOG 4889 4905	Union européenne
#161	AnnotatorNotes T161	C0015179
T162	CHEM 4911 4918	Tysabri
#162	AnnotatorNotes T162	C1529600
T163	CHEM 5000 5007	Tysabri
#163	AnnotatorNotes T163	C1529600
T164	CHEM 5033 5040	Tysabri
#164	AnnotatorNotes T164	C1529600
T165	CHEM 5043 5050	TYSABRI
#165	AnnotatorNotes T165	C1529600
T166	OBJC 5058 5066	solution
#166	AnnotatorNotes T166	C0037633
T167	PROC 5081 5090	perfusion
#167	AnnotatorNotes T167	C0031001
T168	OBJC 5108 5116	solution
#168	AnnotatorNotes T168	C0037633
T169	CHEM 5144 5155	natalizumab
#169	AnnotatorNotes T169	 C1172734
T170	CHEM 5163 5174	natalizumab
#170	AnnotatorNotes T170	C1172734
T171	CHEM 5182 5191	anticorps
#171	AnnotatorNotes T171	C0003241
T172	ANAT 5253 5270	lignée cellulaire
#172	AnnotatorNotes T172	C0007600
T173	ANAT 5260 5270	cellulaire
#173	AnnotatorNotes T173	C0007634
T174	OBJC 5345 5353	solution
#174	AnnotatorNotes T174	C0037633
T175	PROC 5359 5368	perfusion
#175	AnnotatorNotes T175	C0031001
T176	CHEM 5403 5414	natalizumab
#176	AnnotatorNotes T176	C1172734
T177	CHEM 5419 5426	TYSABRI
#177	AnnotatorNotes T177	C1529600
T178	PROC 5461 5471	traitement
#178	AnnotatorNotes T178	C0087111
T179	DISO 5507 5526	sclérose en plaques
#179	AnnotatorNotes T179	C0026769
T180	DISO 5529 5532	SEP
#180	AnnotatorNotes T180	C0026769
T181	LIVB 5566 5573	groupes
#181	AnnotatorNotes T181	C1257890
T182	LIVB 5577 5585	patients
#182	AnnotatorNotes T182	C0030705
T183	LIVB 5601 5609	Patients
#183	AnnotatorNotes T183	C0030705
T184	DISO 5649 5656	maladie
#184	AnnotatorNotes T184	C0012634
T185	PROC 5667 5677	traitement
#185	AnnotatorNotes T185	C0087111
T186	CHEM 5682 5697	interféron bêta
#186	AnnotatorNotes T186	C0015980
T187	LIVB 5727 5735	Patients
#187	AnnotatorNotes T187	C0030705
T188	DISO 5751 5770	sclérose en plaques
#188	AnnotatorNotes T188	C0026769
T189	PROC 5851 5861	traitement
#189	AnnotatorNotes T189	C0087111
T190	CHEM 5866 5873	TYSABRI
#190	AnnotatorNotes T190	C1529600
T191	LIVB 5914 5922	médecins
#191	AnnotatorNotes T191	C0031831
T192	LIVB 5923 5935	spécialistes
#192	AnnotatorNotes T192	C0087009
T193	DISO 5962 5972	diagnostic
#193	AnnotatorNotes T193	C0011900
T194	PROC 5979 5989	traitement
#194	AnnotatorNotes T194	C0087111
T195	DISO 5994 6018	affections neurologiques
#195	AnnotatorNotes T195	C0525841
T196	DISO 5994 6004	affections
#196	AnnotatorNotes T196	C0012634
T197	LIVB 6080 6088	patients
#197	AnnotatorNotes T197	C0030705
T198	PROC 6089 6096	traités
#198	AnnotatorNotes T198	C0087111
T199	CHEM 6101 6108	TYSABRI
#199	AnnotatorNotes T199	C1529600
T200	LIVB 6136 6143	patient
#200	AnnotatorNotes T200	C0030705
T201	DISO 6231 6247	hypersensibilité
#201	AnnotatorNotes T201	C0020517
T202	PROC 6274 6277	IRM
#202	AnnotatorNotes T202	C0024485
T203	LIVB 6327 6334	médecin
#203	AnnotatorNotes T203	C0031831
T204	PHYS 6366 6383	immunosuppression
#204	AnnotatorNotes T204	C0021080
T205	PROC 6410 6420	traitement
#205	AnnotatorNotes T205	C0087111
T206	CHEM 6425 6432	TYSABRI
#206	AnnotatorNotes T206	C1529600
T207	PROC 6453 6463	traitement
#207	AnnotatorNotes T207	C0087111
T208	LIVB 6511 6519	patients
#208	AnnotatorNotes T208	C0030705
T209	CHEM 6660 6671	natalizumab
#209	AnnotatorNotes T209	C1172734
T210	PROC 6712 6722	traitement
#210	AnnotatorNotes T210	C0087111
T211	LIVB 1393 1403	partenaire
#211	AnnotatorNotes T211	C0682323
T212	DISO 3211 3245	inflammation du nez et de la gorge
#212	AnnotatorNotes T212	C0027441
T213	ANAT 3344 3365	douleurs articulaires
#213	AnnotatorNotes T213	C0003862
T214	LIVB 4229 4254	sujets de moins de 18 ans
#214	AnnotatorNotes T214	C0205653 C0008059
T216	LIVB 5271 5277	murine
#216	AnnotatorNotes T216	C0026809
T217	DISO 2110 2118	handicap
#217	AnnotatorNotes T217	C0231172
T218	DISO 2378 2390	handicapants
#218	AnnotatorNotes T218	C0231172
T219	LIVB 1695 1716	modèles expérimentaux
#219	AnnotatorNotes T219	C0599779
T220	PROC 1900 1910	administré
#220	AnnotatorNotes T220	C3469597
